Beacon’s Bold Move: Unifying Sleep and Brain Tech to Remake Home Diagnostics

BOSTON, MA – June 10, 2026 – In a move that signals a significant shift in the landscape of home-based healthcare, Beacon Biosignals has announced the full integration of CleveMed and its well-regarded SleepView® testing service into the Beacon brand. This is far more than a corporate rebranding; it represents the strategic fusion of two powerful forces in modern diagnostics: CleveMed’s established, large-scale home sleep apnea testing infrastructure and Beacon’s cutting-edge, AI-driven platform for analyzing brain activity.

The unification creates a single, formidable entity poised to deliver a new category of diagnostics—one that captures a holistic view of a patient’s health by monitoring both brain and body from the comfort of their home. By combining Beacon's expertise in precision neurobiomarkers with CleveMed's operational prowess, the company is making a clear bet on a future where complex neurological and sleep assessments are no longer confined to the hospital or specialized lab.

“Bringing CleveMed fully into the Beacon brand unifies our vision in delivering a new category of home sleep diagnostics,” said Jacob Donoghue, MD, PhD, co-founder and CEO of Beacon Biosignals, in the announcement. “We are combining operational scale with brain-first technology to create the most advanced EEG-based home sleep testing platform in the country.”

A Strategic Consolidation in a Booming Market

Beacon’s move is a calculated play within two rapidly expanding and converging markets: home sleep testing and neuro-diagnostics. The global market for home sleep apnea testing devices, valued at over $1.2 billion in 2024, is projected to surge past $5.5 billion by 2034. This explosive growth is fueled by rising public awareness of sleep disorders, an aging population, and a strong patient preference for convenient, cost-effective diagnostic solutions—a trend massively accelerated by the recent shift toward remote healthcare.

Simultaneously, the neuro-diagnostics market, valued at over $19 billion, is also on a steady growth trajectory, driven by the increasing prevalence of neurological conditions like Alzheimer's and Parkinson's disease. Here, the demand is for more precise, non-invasive tools that can provide early and objective measures of brain health. Beacon is positioning itself at the very intersection of these two powerful currents.

The groundwork for this consolidation was laid in April 2025 with Beacon's acquisition of CleveMed, followed by a substantial, oversubscribed $86 million Series B funding round in November 2025. That capital was explicitly earmarked to build the world's largest neurodiagnostic dataset and advance the clinical application of AI-driven biomarkers. This brand unification is the logical and powerful culmination of that strategy, transforming financial investment into a cohesive market-facing platform.

Unifying Two Worlds: Brain Waves and Breathing

At the heart of this integration is the synergy between two distinct but complementary technologies. On one side is Beacon's proprietary Waveband, an FDA 510(k)-cleared dry-electrode EEG headband. This device, already a key tool in clinical trials with major pharmaceutical partners, captures clinical-grade data on brain activity over multiple nights at home. This data is then fed into Beacon's AI platform, which has been trained on hundreds of thousands of hours of EEG recordings to identify subtle patterns and biomarkers related to neurological and psychiatric conditions.

On the other side is CleveMed’s SleepView®, a trusted Type III home sleep test that measures the standard cardiopulmonary signals—airflow, respiratory effort, blood oxygen levels, and heart rate—essential for diagnosing obstructive sleep apnea. Crucially, CleveMed also brings the SleepView Direct service, a nationwide logistics and support network that handles everything from device shipment to patient support, removing a significant operational burden from healthcare providers.

By uniting these capabilities, Beacon can now offer a comprehensive assessment that was previously impossible to achieve at scale in a home setting. The platform can now correlate nuanced changes in a patient’s sleep architecture, detected by the EEG, with the physiological events of a sleep disorder. This creates a much richer, more contextualized data set, allowing clinicians and researchers to understand not just if a patient stops breathing, but how those events impact their brain function.

“SleepView was built on a simple commitment to make high-quality sleep diagnostics accessible to patients wherever they are,” noted Hani Kayyali, the former CEO of CleveMed who now leads Beacon’s sleep testing business. “Joining Beacon is the natural next step in that mission. I’m confident in Beacon’s ability to build on what CleveMed's customers have come to rely on, while adding capabilities that were simply not possible before.”

The Competitive Edge: AI-Powered Precision at Scale

While the home diagnostics market includes formidable players like ZOLL Medical (with its Itamar Medical WatchPAT) and ResMed, Beacon's integrated platform carves out a unique competitive advantage. Many home sleep tests focus primarily on respiratory function. Others have begun to incorporate AI or limited EEG channels. Beacon’s approach is different in its depth and focus.

Its primary differentiator is its powerful, research-grade AI engine applied to clinical-grade, longitudinal EEG data. This system goes beyond simple sleep staging; it is designed to discover and validate novel neuro-biomarkers for patient stratification and measuring treatment response in clinical trials. By integrating CleveMed's vast operational reach, Beacon is now positioned to deploy this powerful research engine into the broader world of clinical diagnostics.

“What Beacon is building is more than just a better sleep test; it's a scalable platform for real-world evidence generation in neurology,” an industry analyst observed. “They are leveraging an established logistics network to deploy a technology originally honed for the rigors of pharmaceutical R&D. That combination of scale and scientific precision is unique.” This allows the company to create a feedback loop where data from routine clinical care can be used to further refine its AI models, accelerating discovery and improving diagnostic accuracy for everyone.

The Human Impact: From Clinical Trials to Patient Care

Ultimately, the success of this strategy will be measured by its impact on patients and the healthcare system. For individuals, the benefits are clear: a more convenient, less intimidating diagnostic process that can deliver deeper insights. A patient being evaluated for early cognitive decline, for example, could undergo a comprehensive home study that assesses both sleep apnea and subtle EEG markers associated with neurodegeneration, providing their doctor with a more complete picture.

For physicians and researchers, the platform promises access to richer, more objective data that can guide personalized treatment and accelerate the development of new therapies for sleep, neurological, and psychiatric disorders. The assurance of uninterrupted service for existing SleepView customers underscores a commitment to a smooth transition, ensuring that the operational excellence providers have come to expect will continue under the new, unified brand.

By bringing together scalable logistics, advanced hardware, and sophisticated AI, Beacon Biosignals is not just consolidating two companies. It is actively architecting a future where the complex relationship between how we sleep and how our brain functions can be understood with unprecedented clarity and accessibility, moving advanced diagnostics from the specialized lab directly into the patient's home.